AR054195A1 - Derivados de indol como inhibidores de la fosfolipasa a2 citosolica y composicion farmaceutica que los contiene - Google Patents
Derivados de indol como inhibidores de la fosfolipasa a2 citosolica y composicion farmaceutica que los contieneInfo
- Publication number
- AR054195A1 AR054195A1 ARP060102198A ARP060102198A AR054195A1 AR 054195 A1 AR054195 A1 AR 054195A1 AR P060102198 A ARP060102198 A AR P060102198A AR P060102198 A ARP060102198 A AR P060102198A AR 054195 A1 AR054195 A1 AR 054195A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- inhibitors
- phospholipase
- 3alkyl
- quinolin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102100037611 Lysophospholipase Human genes 0.000 title abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 108010058864 Phospholipases A2 Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 quinolin-5-yl Chemical group 0.000 abstract 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 239000000460 chlorine Substances 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Substances 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 108020002496 Lysophospholipase Proteins 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- AQTFKGDWFRRIHR-UHFFFAOYSA-L 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;cobalt(2+);hydron Chemical compound [Co+2].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 AQTFKGDWFRRIHR-UHFFFAOYSA-L 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 102000003658 Group IV Phospholipases A2 Human genes 0.000 abstract 1
- 108010082107 Group IV Phospholipases A2 Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 108010064785 Phospholipases Proteins 0.000 abstract 1
- 102000015439 Phospholipases Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 239000013000 chemical inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de indol como inhibidores químicos de la actividad de diversas enzimas fosfolipasa, particularmente de las enzimas fosfolipasa A2 citosolica (cPLA2), más particularmente incluyendo inhibidores de las enzimas fosfolipasa A2 alfa citosolica (cPLA2alfa). En algunas modalidades, los inhibidores poseen la formula (1). Se proveen también posicion farmacéutica que los contiene. Reivindicacion 1: Un compuesto que tiene la formula (1), en la cual: n1 es 1 o 2; n2 es 1 o 2; n3 es 1 o 2; n5 es 0, 1, o 2; X2 es un enlace O, -CH2- o SO2; cada R5 es independientemente H o alquilo C1-3; R6 es H alquilo C1-6; R7 es seleccionado del grupo que consiste de OH, benciloxi, CH3, CF3, OCF3, alcoxi C1-3, halogeno, COH, COalquilC1-3, CO(OalquilC1-3), quinolin-5-ilo, quinolin-8-ilo, 3,5-dimetilsoxazol-4-ilo, tiofen-3-ilo, piridin-4-ilo, piridin-3-ilo, -CH2-Q, y fenilo opcionalmente sustituido con desde uno hasta tres grupos R30 independientemente seleccionados; R8 es seleccionado del grupo que consiste de H, OH, NO2, CF3, OCF3, alcoxi C1-3, halogeno, COalquilC1-3, CO(OalquilC1-3), quinolin-5-ilo, quinolin-8-ilo, 3,5-dimetilsoxazol-4-ilo, tiofen-3-ilo, -CH2-Q, y fenilo sustituido por desde uno hasta tres grupos R30 independientemente seleccionados; Q es OH, dialquilamino, o un grupo de formulas (2) o (3); R20 es seleccionado del grupo que consiste de H, alquilo C1-3 y COalquilC1-3); y R30 es seleccionado del grupo que consiste de dialquilamino, CN y OCF3; con la condicion que: a) cuando cada R5 es H, R6 es H, n5 es 0, y R8 es H, entonces R7 no puede ser cloro; b) cuando cada R5 es H, R6 es H, n5 es 0, X2 es O o -CH2-, y R8 es H, entonces R7 no puede ser CH3; c) cuando cada R5 es H, y R6 es H, entonces R7 y R8 no pueden ser ambos fluor; d) cuando cada R5 es H, R6 es H, y X2 es O, entonces R7 y R8 no pueden ser ambos cloro; e) cuando cada R5 es H, R6 es H, X2 es O, y R8 es NO2, entonces R7 no puede ser fluor; y f) cuando cada R5 es H, R6 es H, X2 es SO2, y R8 es H, entonces R7 no puede ser fluor o cloro; o una sal farmacéuticamente aceptable de lo mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68556405P | 2005-05-27 | 2005-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054195A1 true AR054195A1 (es) | 2007-06-06 |
Family
ID=37188759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102198A AR054195A1 (es) | 2005-05-27 | 2006-05-26 | Derivados de indol como inhibidores de la fosfolipasa a2 citosolica y composicion farmaceutica que los contiene |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US7557135B2 (es) |
| EP (2) | EP2248801A1 (es) |
| JP (1) | JP5116666B2 (es) |
| KR (1) | KR101353982B1 (es) |
| CN (2) | CN101184729B (es) |
| AR (1) | AR054195A1 (es) |
| AT (1) | ATE489364T1 (es) |
| AU (1) | AU2006251946B2 (es) |
| BR (1) | BRPI0610049A2 (es) |
| CA (1) | CA2607857C (es) |
| CR (1) | CR9520A (es) |
| CY (1) | CY1111151T1 (es) |
| DE (1) | DE602006018451D1 (es) |
| DK (1) | DK1891006T3 (es) |
| ES (1) | ES2354908T3 (es) |
| GT (1) | GT200600228A (es) |
| HN (1) | HN2006019513A (es) |
| IL (1) | IL186912A (es) |
| MX (1) | MX2007014589A (es) |
| MY (1) | MY144672A (es) |
| NI (1) | NI200700287A (es) |
| NO (1) | NO20075627L (es) |
| NZ (1) | NZ563736A (es) |
| PE (1) | PE20061426A1 (es) |
| PL (1) | PL1891006T3 (es) |
| PT (1) | PT1891006E (es) |
| RU (1) | RU2433997C2 (es) |
| SI (1) | SI1891006T1 (es) |
| SV (1) | SV2008002551A (es) |
| TW (1) | TW200718687A (es) |
| UA (1) | UA91053C2 (es) |
| WO (1) | WO2006128142A2 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713964B2 (en) | 2001-12-03 | 2010-05-11 | Wyeth Llc | Methods for treating asthmatic conditions |
| US7605156B2 (en) | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
| HN2004000536A (es) * | 2003-12-16 | 2009-02-18 | Wyeth Corp | Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles |
| IL161579A0 (en) | 2004-04-22 | 2004-09-27 | Mor Research Applic Ltd | ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF |
| EP1744761A4 (en) | 2004-04-28 | 2010-01-13 | Molecules For Health Inc | METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER |
| TW200718687A (en) * | 2005-05-27 | 2007-05-16 | Wyeth Corp | Inhibitors of cytosolic phospholipase A2 |
| US20080009485A1 (en) * | 2006-05-26 | 2008-01-10 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis |
| IL178401A (en) | 2006-09-28 | 2012-04-30 | Univ Ben Gurion | Use of antisense oligonucleotides against 2 cPLA in the treatment of cancer |
| EP2104498A2 (en) * | 2006-10-31 | 2009-09-30 | Wyeth | Liquid formulations of phospholipase enzyme inhibitors |
| BRPI0718042A2 (pt) * | 2006-10-31 | 2013-11-12 | Wyeth Corp | Formulações semissólidas de inibidores de enzima fosfolipase |
| ES2422284T3 (es) | 2007-03-29 | 2013-09-10 | Daiichi Sankyo Co Ltd | Derivado de indol que tiene actividad inhibidora de cPLA2, uso del mismo y método para producirlo |
| US9526707B2 (en) | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
| EP2583099B1 (en) | 2010-06-18 | 2016-11-02 | Whitehead Institute for Biomedical Research | Pla2g16 as a target for antiviral compounds |
| WO2012031763A1 (en) | 2010-09-08 | 2012-03-15 | Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh | Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection |
| GB201401904D0 (en) * | 2014-02-04 | 2014-03-19 | Ziarco Pharma Ltd | Pharmaceutical composition for topical administration |
| CN106061938B (zh) | 2014-02-28 | 2019-04-12 | 住友化学株式会社 | 2-(卤代甲基)-3-甲基硝基苯的制造方法 |
| CN103804150A (zh) * | 2014-03-01 | 2014-05-21 | 江苏斯威森生物医药工程研究中心有限公司 | 一种3,4-二甲氧基苄基溴的制备方法 |
| CN108017522B (zh) * | 2017-11-16 | 2021-01-05 | 贵州大学 | 一种2,6-二溴苯甲磺酰氯的制备工艺 |
| WO2020236777A1 (en) * | 2019-05-20 | 2020-11-26 | Saint Louis University | Reprogramming of lipid metabolism to inhibit t cell senescence and enhance tumor immunotherapy |
| TW202235416A (zh) | 2019-06-14 | 2022-09-16 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| EP4126231A1 (en) | 2020-03-30 | 2023-02-08 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| PL4126862T3 (pl) * | 2020-04-02 | 2025-09-08 | Gilead Sciences, Inc. | Sposób wytwarzania związku będącego inhibitorem cot |
| WO2022031931A2 (en) * | 2020-08-06 | 2022-02-10 | The Children's Medical Center Corporation | Compositions for altering a microglial cell, and methods of use therefore |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH48411A (fr) | 1909-07-19 | 1910-10-17 | Stephen Alley | Outillage pour mettre en place et enlever les bandages élastiques des roues de véhicules |
| GB1148908A (en) | 1965-04-19 | 1969-04-16 | Sumitomo Chemical Co | Indole derivatives and processes for making them |
| FR1492929A (fr) | 1966-05-11 | 1967-08-25 | Roussel Uclaf | Nouveaux 1-(omega-carboxyalcoyl) indoles substitués et procédé de préparation |
| US3505354A (en) | 1967-05-18 | 1970-04-07 | Geigy Chem Corp | 2-methyl-3-p-halobenzoylindole-n-aliphatic acids |
| DE1816335A1 (de) | 1968-12-21 | 1970-07-09 | Thiemann Gmbh Chem Pharm Fabri | Verfahren zur Herstellung von [2-Methyl-5-alkoxy-3-acyl-indol-1]-essigsaeuren und deren Estern |
| US3931229A (en) | 1973-08-23 | 1976-01-06 | Warner-Lambert Company | 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4271263A (en) | 1980-05-15 | 1981-06-02 | Minnesota Mining And Manufacturing Company | Thermally developable photosensitive compositions containing acutance agents |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4654360A (en) | 1984-06-01 | 1987-03-31 | Syntex (U.S.A.) Inc. | 1,2,3-trisubstituted indoles for treatment of inflammation |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4894386A (en) | 1987-04-15 | 1990-01-16 | Ici Americas Inc. | Aliphatic carboxamides |
| AU623897B2 (en) | 1988-04-13 | 1992-05-28 | Ici Americas Inc. | Indolyl and indazolyl cyclic amides |
| GB8906032D0 (en) | 1988-04-14 | 1989-04-26 | Ici America Inc | Hetera-aliphatic carboxamides |
| US5166170A (en) | 1989-07-03 | 1992-11-24 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
| GB8916774D0 (en) | 1989-07-21 | 1989-09-06 | Bayer Ag | New indole derivatives,a process for their preparation and their use in medicaments |
| US5420289A (en) | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| US5229516A (en) | 1989-10-27 | 1993-07-20 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| PT95692A (pt) | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| US5081145A (en) | 1990-02-01 | 1992-01-14 | Merck Frosst Canada, Inc. | Indole-2-alkanoic acids compositions of and anti allergic use thereof |
| US5622832A (en) | 1990-02-28 | 1997-04-22 | Genetics Institute, Inc. | Arachidonic acid releasing phospholipase A2 enzyme and methods of use |
| US5290798A (en) | 1991-09-30 | 1994-03-01 | Merck Frosst Canada, Inc. | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| US5190968A (en) | 1991-09-30 | 1993-03-02 | Merck Frosst Canada, Inc. | (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
| US5206377A (en) | 1991-12-05 | 1993-04-27 | Whitby Research, Inc. | Compounds useful as antiproliferative agents |
| DK0640080T3 (da) | 1992-05-13 | 1998-05-25 | Syntex Inc | Substituerede indoler som angiotensin II antagonister |
| US5212195A (en) | 1992-05-13 | 1993-05-18 | Syntex (U.S.A.) Inc. | Substituted indole antagonists derivatives which are angiotensin II |
| US5288743A (en) | 1992-11-20 | 1994-02-22 | Abbott Laboratories | Indole carboxylate derivatives which inhibit leukotriene biosynthesis |
| ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| US5424329A (en) | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
| DE4338770A1 (de) | 1993-11-12 | 1995-05-18 | Matthias Dr Lehr | Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ |
| US5686481A (en) | 1993-12-21 | 1997-11-11 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US5641800A (en) | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| US5482960A (en) | 1994-11-14 | 1996-01-09 | Warner-Lambert Company | Nonpeptide endothelin antagonists |
| AU3767997A (en) | 1996-08-01 | 1998-02-25 | Merckle Gmbh | Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2 |
| AU717430B2 (en) | 1996-08-26 | 2000-03-23 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| BR9909242A (pt) | 1998-02-25 | 2000-11-14 | Genetics Inst | Inibidores de fosfolipase a2 |
| CN1310706A (zh) | 1998-02-25 | 2001-08-29 | 遗传研究所有限公司 | 磷脂酶抑制剂 |
| SK12742000A3 (sk) * | 1998-02-25 | 2001-05-10 | Genetics Institute, Inc. | Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6424105B1 (en) | 1999-06-08 | 2002-07-23 | Camco International, Inc. | Real-time control of feedback signals to a motor for optimum performance |
| US20030149209A1 (en) | 2001-01-22 | 2003-08-07 | Yasuhito Inagaki | Solvent absorbing resin and method for preparation thereof |
| US6635771B2 (en) | 2001-12-03 | 2003-10-21 | Wyeth | N-benzhydryl indole compounds |
| PL370445A1 (en) * | 2001-12-03 | 2005-05-30 | Wyeth | Inhibitors of cytosolic phospholipase a2 |
| US6984735B2 (en) | 2001-12-03 | 2006-01-10 | Wyeth | Process for making an aldehyde |
| US6797708B2 (en) * | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
| US7713964B2 (en) * | 2001-12-03 | 2010-05-11 | Wyeth Llc | Methods for treating asthmatic conditions |
| US7101875B2 (en) * | 2001-12-03 | 2006-09-05 | Wyeth | Methods for treating arthritic disorders |
| US7605156B2 (en) | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
| US7439249B2 (en) | 2002-12-31 | 2008-10-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatases |
| CA2511925C (en) | 2002-12-31 | 2012-11-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of phosphatases, compositions and uses thereof |
| TW200510305A (en) | 2003-07-25 | 2005-03-16 | Wyeth Corp | Process for the preparation of CPLA2 inhibitors |
| US7582771B2 (en) | 2003-09-03 | 2009-09-01 | Wyeth | Process for the synthesis of cPLA2 inhibitors |
| US20050053600A1 (en) | 2003-09-09 | 2005-03-10 | Lane Thomas E. | Methods for treating rheumatoid arthritis |
| US7342119B2 (en) | 2003-09-30 | 2008-03-11 | Wyeth Holdings Corporation | Process for the synthesis of a CPLA2 inhibitor |
| HN2004000536A (es) | 2003-12-16 | 2009-02-18 | Wyeth Corp | Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles |
| AR053410A1 (es) | 2004-08-19 | 2007-05-09 | Wyeth Corp | Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios |
| TW200718687A (en) | 2005-05-27 | 2007-05-16 | Wyeth Corp | Inhibitors of cytosolic phospholipase A2 |
| US20080009485A1 (en) * | 2006-05-26 | 2008-01-10 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis |
-
2006
- 2006-05-25 TW TW095118534A patent/TW200718687A/zh unknown
- 2006-05-25 GT GT200600228A patent/GT200600228A/es unknown
- 2006-05-26 BR BRPI0610049-0A patent/BRPI0610049A2/pt not_active IP Right Cessation
- 2006-05-26 ES ES06771540T patent/ES2354908T3/es active Active
- 2006-05-26 SI SI200630865T patent/SI1891006T1/sl unknown
- 2006-05-26 CN CN2006800186466A patent/CN101184729B/zh not_active Expired - Fee Related
- 2006-05-26 NZ NZ563736A patent/NZ563736A/en not_active IP Right Cessation
- 2006-05-26 CN CN2010105355308A patent/CN102040550B/zh not_active Expired - Fee Related
- 2006-05-26 AR ARP060102198A patent/AR054195A1/es not_active Application Discontinuation
- 2006-05-26 HN HN2006019513A patent/HN2006019513A/es unknown
- 2006-05-26 JP JP2008513819A patent/JP5116666B2/ja not_active Expired - Fee Related
- 2006-05-26 MX MX2007014589A patent/MX2007014589A/es active IP Right Grant
- 2006-05-26 SV SV2006002551A patent/SV2008002551A/es unknown
- 2006-05-26 CA CA2607857A patent/CA2607857C/en active Active
- 2006-05-26 DK DK06771540.9T patent/DK1891006T3/da active
- 2006-05-26 RU RU2007140910/04A patent/RU2433997C2/ru not_active IP Right Cessation
- 2006-05-26 PE PE2006000559A patent/PE20061426A1/es not_active Application Discontinuation
- 2006-05-26 PL PL06771540T patent/PL1891006T3/pl unknown
- 2006-05-26 AU AU2006251946A patent/AU2006251946B2/en not_active Ceased
- 2006-05-26 PT PT06771540T patent/PT1891006E/pt unknown
- 2006-05-26 DE DE602006018451T patent/DE602006018451D1/de active Active
- 2006-05-26 KR KR1020077027672A patent/KR101353982B1/ko not_active Expired - Fee Related
- 2006-05-26 MY MYPI20062443A patent/MY144672A/en unknown
- 2006-05-26 EP EP10172388A patent/EP2248801A1/en not_active Withdrawn
- 2006-05-26 AT AT06771540T patent/ATE489364T1/de active
- 2006-05-26 WO PCT/US2006/020847 patent/WO2006128142A2/en not_active Ceased
- 2006-05-26 US US11/442,199 patent/US7557135B2/en active Active
- 2006-05-26 EP EP06771540A patent/EP1891006B1/en not_active Not-in-force
- 2006-05-26 UA UAA200713220A patent/UA91053C2/ru unknown
-
2007
- 2007-10-25 IL IL186912A patent/IL186912A/en active IP Right Grant
- 2007-11-06 NO NO20075627A patent/NO20075627L/no not_active Application Discontinuation
- 2007-11-09 NI NI200700287A patent/NI200700287A/es unknown
- 2007-11-14 CR CR9520A patent/CR9520A/es not_active Application Discontinuation
-
2009
- 2009-06-19 US US12/488,182 patent/US8283373B2/en active Active
- 2009-06-19 US US12/488,020 patent/US20100029645A1/en not_active Abandoned
-
2010
- 2010-12-09 CY CY20101101135T patent/CY1111151T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054195A1 (es) | Derivados de indol como inhibidores de la fosfolipasa a2 citosolica y composicion farmaceutica que los contiene | |
| AR054799A1 (es) | Derivados de oxindol | |
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| PE20040688A1 (es) | Inhibidores de quinasas | |
| PE20121172A1 (es) | Piperidinas sustituidas con actividad en la hdm2 | |
| AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
| AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
| CO4990929A1 (es) | Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8 | |
| BRPI0612888A8 (pt) | anilino-piridinotriazinas cíclicas | |
| BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
| NO20075111L (no) | Farmasoytisk sammensetning | |
| PE20070602A1 (es) | Compuestos de carboxiamina como moduladores de histona desacetilasa | |
| CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
| AR053748A1 (es) | Entidades quimicas, composiciones y metodos. | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR058077A1 (es) | Derivados de acidos fenoxiaceticos | |
| PE20050226A1 (es) | Productos aril-heteroaromaticos y composiciones que los contienen | |
| CR8468A (es) | Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1 | |
| UY27716A1 (es) | Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo. | |
| AR074053A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienen | |
| ES2255190T3 (es) | Compuestos indol 2,3-sustituidos como inhibidores de cox-2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |